The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).
Derek J. Jonker
No relevant relationships to disclose
Louise M. Nott
No relevant relationships to disclose
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck Serono; Takeda
Research Funding - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Yakult
Chiang Li
Employment or Leadership Position - Boston Biomedical; Dainippon Sumitomo Pharma
Sharlene Gill
No relevant relationships to disclose
Jeremy David Shapiro
No relevant relationships to disclose
Atsushi Ohtsu
Employment or Leadership Position - Celgene (I)
John Raymond Zalcberg
No relevant relationships to disclose
Michael M. Vickers
No relevant relationships to disclose
John Simes
No relevant relationships to disclose
Alice Chia-chi Wei
No relevant relationships to disclose
Nicole Mittmann
No relevant relationships to disclose
Nadine M Magoski
No relevant relationships to disclose
Yvonne Murray
No relevant relationships to disclose
Eric Tsobanis
No relevant relationships to disclose
Dongsheng Tu
No relevant relationships to disclose
David Kerstein
Employment or Leadership Position - Boston Biomedical
Christopher J. O'Callaghan
No relevant relationships to disclose